Novartis to Seek Heart Drug Approval After Test Ends Early
This article is for subscribers only.
Novartis AG plans to seek approval of a medicine for chronic heart failure sooner than expected, advancing its effort to build a portfolio of cardiac therapies.
The drugmaker is ending a late-stage clinical trial of an experimental medicine known as LCZ696 early after the results showed patients treated with it lived longer without being hospitalized than a group who got standard treatment, the Basel, Switzerland-based company said in a statement today.